Internal Server Error

XtalPi - About the company

XtalPi is a public company based in Cambridge (United States), founded in 2014 by Shuhao Wen, Lipeng Lai, Jie Ren and Jian Ma. It operates as an AI-based drug research and development company. XtalPi has raised $785M in funding from investors like Orbimed, Tencent and Renren. The company has 257 active competitors, including 82 funded and 15 that have exited. Its top competitors include companies like Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics.

Company Details

XtalPi has developed a proprietary technology FACES(Fast Accurate Crystalline Engineering System), which is a cloud-based computing system to predict the crystal structure which will identify polymorphs of the compound. The company's algorithms are integrated with the Amazon Web Service (AWS) high-performance computing (HPC) resources in the cloud. The team claims to have a strong background in quantum physics and machine learning. It provides services to pharmaceutical companies at various stages of drug development. The company has deployed its technology to develop an Intelligent Digital Drug Discovery and Development (ID4) platform to improve the efficiency, accuracy, and success rate of drug discovery.
Social
X
Key Metrics
Founded Year
2014
Location
Cambridge, United States
Stage
Public
Total Funding
$785M in 8 rounds
Latest Funding Round
Investors
Ranked
Employee Count
393 as on Sep 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public

XtalPi's IPO details

XtalPi got listed on Jun 13, 2024.
Click here to take a look at XtalPi's IPO in detail
Sign up to download XtalPi's company profile

XtalPi's funding and investors

XtalPi has raised a total funding of $785M over 8 rounds. XtalPi has 27 institutional investors.

Here is the list of recent funding rounds of XtalPi:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Sep 17, 2025
$268M
Post IPO
-
-
-
-
Feb 27, 2025
$268M
Post IPO
-
-
-
-
Aug 11, 2021
$400M
Series D
$2.01B
-
lockAccess funding benchmarks and valuations. Sign up today!

XtalPi's founders and board of directors

Founder? Claim Profile
The founders of XtalPi are Shuhao Wen, Lipeng Lai, Jie Ren and Jian Ma.
Here are the details of XtalPi's key team members:

XtalPi's employee count trend

XtalPi has 393 employees as of Sep 26. Here is XtalPi's employee count trend over the years:
Employee count trend for XtalPi
lockUncover XtalPi's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

XtalPi's Competitors and alternates

Top competitors of XtalPi include Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics. Here is the list of Top 10 competitors of XtalPi, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Schrodinger
Schrodinger
1990, New York City (United States), Acquired
Provider of a web-based simulation and modelling tool
$162M
74/100
2nd
AI-enabled drug discovery and development platform for novel therapeutics
$452M
72/100
3rd
Logo for Relay Therapeutics
Relay Therapeutics
2016, Cambridge (United States), Public
Developer of drug discovery platform and study protein motion
$520M
70/100
4th
Logo for Atomwise
Atomwise
2012, San Francisco (United States), Series B
Developer of artificial intelligence platform for small molecule drug discovery
$219M
67/100
5th
Logo for Valo Health
Valo Health
2019, Boston (United States), Series B
AI-powered platform for drug discovery and development
$450M
67/100
6th
Logo for XtalPi
XtalPi
2014, Cambridge (United States), Public
AI-based drug research and development company
$785M
67/100
7th
Logo for Isomorphic Labs
Isomorphic Labs
2021, London (United Kingdom), Series B
Digital platform focused on revolutionizing drug discovery using AI
$2.7B
64/100
8th
Logo for Xaira
Xaira
2023, San Francisco (United States), Series D
AI-enabled platform for drug discovery and development
$1B
63/100
9th
Logo for In Silico
In Silico
2014, Boston (United States), Public
AI-enabled bioinformatics platform for drug discovery and biomarker development
$510M
62/100
10th
Logo for Tandem AI
Tandem AI
2021, New York (United States), Series A
AI-based drug discovery tool for researchers
$82M
62/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on XtalPi's competitors? Click here to see the top ones

XtalPi's Investments and acquisitions

XtalPi has made 5 investments in companies including ReviR Therapeutics and CytoCan. XtalPi has also acquired 1 companies including Liverpool ChiroChem.
Here is the list of investments & acquisitions:lockFilter this list
Date of Investment/Acquisition
Type
Company Name
Founded Year
Location
Jun 13, 2025
Acquisition
2014
Liverpool (United Kingdom)
Jul 26, 2024
Investments
2021
San Francisco (United States)
Feb 07, 2023
Investments
2022
Hangzhou (China)
lockWant to know more about where corporates are investing? Sign up today!
See all investments by XtalPi

Reports related to XtalPi

Here is the latest report on XtalPi's sector:

News related to XtalPi

lockFilter this list
Media has covered XtalPi for a total of 12 events in the last 1 year, 4 of them have been about company updates and 3 about partnerships.
•
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about XtalPi

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford